Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 11/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.40 |
| ▸ | TNKS | O95271 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314102 | 1.00 | AVPR1A (0.43) | AVPR1ATNKS2TNKSOPRL1DCTPP1 | |
| SCHEMBL314101 | 1.00 | AVPR1A (0.43) | AVPR1ATNKS2TNKSOPRL1DCTPP1 | |
| SCHEMBL314200 | 0.87 | TNKS2 (0.40) | TNKS2TNKSP2RX7 | |
| SCHEMBL314199 | 0.87 | TNKS2 (0.40) | TNKS2TNKSP2RX7 | |
| SCHEMBL314198 | 0.87 | TNKS2 (0.40) | TNKS2TNKSP2RX7 | |
| SCHEMBL314365 | 0.86 | TNKS2 (0.40) | AVPR1ATNKS2TNKSP2RX7BRD4 | |
| SCHEMBL314713 | 0.86 | TNKS2 (0.40) | AVPR1ATNKS2TNKSP2RX7BRD4 | |
| SCHEMBL314133 | 0.86 | TNKS2 (0.40) | AVPR1ATNKS2TNKSP2RX7BRD4 | |
| SCHEMBL314679 | 0.85 | HSD11B1 (0.41) | AVPR1ATNKS2BRD4OPRK1 | |
| SCHEMBL314677 | 0.85 | HSD11B1 (0.41) | AVPR1ATNKS2BRD4OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | AVPR1A 3270/4885TNKS2 630/4885TNKS 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.